Information  X 
Enter a valid email address


  Print      Mail a friend       Annual reports

Thursday 06 September, 2001



6 September 2001

BTG appoints new non-executive director

London, UK - 6 September 2001 - BTG plc (LSE: BGC), the global technology
commercialisation company, today announced the appointment of Mr Fred G. Weiss
to its Board of Directors as a Non-Executive Director.

Mr Weiss has extensive corporate, healthcare and financial experience and is
currently Managing Director of a private consulting and investment management
firm.  From 1979 to 1996, he held a number of positions with Warner-Lambert
Co., with his final role being Vice President, Planning, Investment and
Development.  In this capacity he was responsible for leading the
corporation's strategic planning, corporate development, venture capital
investments and pension investments.  He was also a member of the Boards of
the Glaxo Wellcome/Warner-Lambert OTC Joint Venture and Warner-Chilcott plc,
now owned by Galen Holdings plc.  Previously, Mr Weiss spent 12 years with
Exxon Corporation where he led various assignments in domestic corporate
finance, international treasury and planning.

Mr Weiss received his B.S. degree from the University of Pennsylvania and his
MBA at the University of Chicago.  He also studied at the London School of

Mr Weiss, who lives in the USA, is a director of a number of Merrill Lynch
mutual funds, Watson Pharmaceuticals, Inc., the Michael J. Fox Foundation for
Parkinson's Research and The Parkinson's Research Action Network.  He is also
a director of a number of private firms in the healthcare field, including the
Kann Institute for Medical Carreers, Inc.



Andy Burrows              Tel:          +44 (0)20 7575 1741
BTG                       E-mail:

Ben Atwell                Tel:          +44 (0)20 7831 3113
Financial Dynamics        E-mail:

Notes to Editors

About BTG

BTG's business is finding, developing and commercialising technologies that
will shape the markets of tomorrow.  Our technologies begin with innovation in
a particular scientific or technical discipline.  Those technologies will be
protected by a strong portfolio of intellectual property.  BTG creates value
by investing in further technical development and enhancing the scope of the
intellectual property.  Finally, BTG captures value by either licensing the
rights to the technology or by developing new business ventures. We return
significant value to our sources of technology, our business partners and our

With headquarters in London and offices in Philadelphia and Tokyo, BTG
capitalises on a global network of contacts in companies, universities and
research institutions to identify and commercialise the most promising
technologies.  Since being founded in 1949, BTG has commercialised such major
innovations as magnetic resonance imaging (MRI), Interferon and wide-spectrum
cephalosporin antibiotics.

BTG is quoted on the London Stock Exchange under the symbol 'BGC'.  BTG's
website includes information about our business and recent
press releases.  In the UK and USA respectively, BTG operates through wholly
owned subsidiaries, BTG International Ltd. and BTG International Inc.